Effect of Thrombopoietin Receptor Agonist Romiplostim on the Ionizing Radiation‐Induced Premature Aging
Pharmacology Research & Perspectives · 2025-12 · 13 (6)
DOI: 10.1002/prp2.70203 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2025-12. Verfasst von Masaru Yamaguchi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Science, Hirosaki University Graduate School of Health Sciences, Hirosaki, Japan. Hauptthemen laut MEDLINE: Thrombopoietin, Aging, Premature, Receptors, Fc, Recombinant Fusion Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Environmental stressors, such as ionizing radiation, accelerate aging by causing DNA damage and triggering pathways that lead to cell cycle arrest, apoptosis, and subsequent inflammation. The thrombopoietin receptor agonist romiplostim (RP), which is used as a clinical treatment for chronic idiopathic thrombocytopenic purpura and aplastic anemia, is known to be promising in reducing radiation‐induced tissue damage. In this study, we established a mouse model of radiation‐induced premature aging to evaluate the potential of RP in ameliorating this process. Female C57BL/6JJcl mice were subjected to total body irradiation with various irradiation schedules. Mice irradiated with 5 Gy every 4 weeks (total dose of 10 Gy over 2 months) showed a significant aging phenotype, including graying hair and elevated serum aging markers (CDKN2A/p16 INK4a , tumor necrosis factor‐α (TNF‐α), and C‐reactive protein), compared with sham‐irradiated controls. RP was intraperitoneally administered to the mouse model (10 μg/kg weekly or 50 μg/kg every 4 weeks). Treatment significantly reduced TNF‐α levels by 15% and the area of graying body hair by 70%. Although bone marrow cell recovery was incomplete, spleen cell counts were significantly restored (2‐fold) by 50 μg/kg RP, and SA‐β‐gal activity, a marker of cellular senescence, was also significantly suppressed by approximately 15%. These findings suggest that RP may partially ameliorate radiation‐induced premature aging, providing a basis for future research addressing health issues associated with aging and radiation exposure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Science, Hirosaki University Graduate School of Health Sciences, Hirosaki, Japan.
- Department of Radiobiology, Institute for Environmental Sciences, Rokkasho, Japan.
- Norris Comprehensive Cancer Center, University of Southern California, California, Los Angeles, USA.
ORCID-Profile: Yoshiaki Sato
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Yamaguchi, M., Hirouchi, T., Sato, Y., & Kashiwakura, I. (2025). Effect of Thrombopoietin Receptor Agonist Romiplostim on the Ionizing Radiation‐Induced Premature Aging. Pharmacology Research & Perspectives, 13(6). https://doi.org/10.1002/prp2.70203
Vancouver
Yamaguchi M, Hirouchi T, Sato Y, Kashiwakura I. Effect of Thrombopoietin Receptor Agonist Romiplostim on the Ionizing Radiation‐Induced Premature Aging. Pharmacology Research & Perspectives. 2025;13(6). doi:10.1002/prp2.70203
BibTeX
@article{Yamaguchi2025,
author = {Yamaguchi, Masaru and Hirouchi, Tokuhisa and Sato, Yoshiaki and Kashiwakura, Ikuo},
title = {Effect of Thrombopoietin Receptor Agonist Romiplostim on the Ionizing Radiation‐Induced Premature Aging},
journal = {Pharmacology Research & Perspectives},
year = {2025},
volume = {13},
number = {6},
doi = {10.1002/prp2.70203}
}
EUVIMED